1192372-11-4

Basic information

• Product Name: Methyl 4-chloro-1H-iMidazole-5-carboxylate
• Synonyms: Methyl 4-chloro-1H-iMidazole-5-carboxylate;methyl 5-chloro-1H-imidazole-4-carboxylate
• CAS NO: 1192372-11-4
• Molecular Formula: C5H5ClN2O2
• Molecular Weight: 160.5584
• Mol File: 1192372-11-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Methyl 4-chloro-1H-iMidazole-5-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-chloro-1H-iMidazole-5-carboxylate(1192372-11-4)
• EPA Substance Registry System: Methyl 4-chloro-1H-iMidazole-5-carboxylate(1192372-11-4)

Safety Data

• Hazardous Substances Data: 1192372-11-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 4-chloro-1H-imidazole-5-carboxylate is used as a key intermediate for the synthesis of antifungal and antibacterial drugs. Its unique chemical structure allows it to be incorporated into the development of new pharmaceuticals that target and combat fungal and bacterial infections effectively.
Used in Agrochemical Industry:
In the agrochemical sector, Methyl 4-chloro-1H-imidazole-5-carboxylate is employed as a building block in the preparation of synthetic organic compounds. These compounds are further utilized in the development of pesticides and other agrochemicals to protect crops from various pests and diseases, ensuring increased agricultural productivity.
Used in Research and Development:
Methyl 4-chloro-1H-imidazole-5-carboxylate is also used as a valuable component in the synthesis of various research and development compounds. Its versatile chemical properties make it suitable for the creation of new organic compounds with potential applications in various fields, including medicine, materials science, and chemical engineering.

Upstream product

• 17325-26-7 Methyl imidazole-4-carboxylate 

Relevant articles and documents

NOVEL INDAZOLE COMPOUND OR SALT THEREOF

An indazole compound represented by the following Formula (I) or a salt thereof: wherein X, R1, R2, ring A, L1, L2, L3, and R5 are as defined in this specification.

ANTICANCER COMBINATION THERAPY WITH N-(1-ACRYLOYL-AZETIDIN-3-YL)-2-((1H-INDAZOL-3-YL)AMINO)METHYL)-1H-IMIDAZOLE-5-CARBOXAMIDE INHIBITOR OF KRAS-G12C

A method of treating cancer comprises administering: (a) a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof; and (b) a therapeutically effective amount of an additional anti-cancer agent, to a subject in need of such treatment, the compound of Formula (I) being: where X, R1, R2, ring A, L1, L2, L3, and R5 are as defined in this disclosure.

KRAS G12D PROTEIN INHIBITORS

Compounds and pharmaceutically acceptable salts thereof inhibit the G12D mutant of KRAS protein and are expected to have utility as therapeutic agents, for example, for the treatment of cancer.

Rational design of potent non-nucleoside inhibitors of HIV-1 reverse transcriptase

A new series of non-nucleoside reverse transcriptase inhibitors based on an imidazole-amide biarylether scaffold has been identified and shown to possess potent antiviral activity against HIV-1, including the NNRTI-resistant Y188L mutated virus. X-ray crystallography of inhibitors bound to reverse transcriptase, including a structure of the Y188L RT protein, was used extensively to help identify and optimize the key hydrogen-bonding motif. This led directly to the design of compound 43 that exhibits remarkable antiviral activity (EC50 1 nM) against a wide range of NNRTI-resistant viruses and a favorable pharmacokinetic profile across multiple species.

CHEMICAL COMPOUNDS

The present invention relates to compounds that are a non-nucleoside reverse transcriptase inhibitors, and to processes for the preparation and use of the same. Specifically, the present invention includes methods of using such compounds in the treatment of human immunodeficiency virus infection.